ERBB2 and breast cancer: PIK3CA alterations are among the most common genomic aberrations seen in patients with HER2-positive BC; data suggest that PIK3CA is altered in 36% of patients [10], with mutations in 30.7%, amplifications in 3.1%, and multiple alterations in 2.1% of cases [37].